Vivoryon Therapeutics N.V. to Participate in Upcoming Conferences
24 Avril 2023 - 07:00AM
Vivoryon Therapeutics N.V. to Participate in Upcoming Conferences
Vivoryon Therapeutics N.V.
to Participate
in Upcoming Conferences
Halle (Saale) / Munich,
Germany, April
24, 2023 – Vivoryon Therapeutics
N.V. (Euronext Amsterdam: VVY; NL00150002Q7)
(Vivoryon), a clinical stage company focused on
the discovery and development of small molecule medicines to
modulate the activity and stability of pathologically altered
proteins, today announced that the Company’s management will
participate in the following investor conferences:
Van Lanschot
Kempen Life Sciences Conference
Amsterdam (April 25-26,
2023)Date: April 25, 2023Only
one-on-one meetingsVenue: Van Lanschot Kempen Office; Amsterdam,
The Netherlands
Bio€quity
Europe (May 14-16, 2023)Date: May
16, 2023Presentation Time: 10:44 am ISTVenue: Convention Centre
Dublin; Dublin, Ireland
###
About Vivoryon Therapeutics
N.V.Vivoryon is a clinical stage biotechnology company
focused on developing innovative small molecule-based medicines.
Driven by our passion for ground-breaking science and innovation,
we strive to change the lives of patients in need suffering from
severe diseases. We leverage our in-depth expertise in
understanding post-translational modifications to develop medicines
that modulate the activity and stability of proteins which are
altered in disease settings. Beyond our lead program,
varoglutamstat, which is in Phase 2 clinical development to treat
Alzheimer’s disease, we have established a solid pipeline of orally
available small molecule inhibitors for various indications
including cancer, inflammatory diseases and fibrosis.
www.vivoryon.com
Vivoryon Forward Looking
StatementsThis press release includes forward-looking
statements, including, without limitation, those regarding the
business strategy, management plans and objectives for future
operations of the Vivoryon Therapeutics N.V. (the “Company”),
estimates and projections with respect to the market for the
Company’s products and forecasts and statements as to when the
Company’s products may be available. Words such as “anticipate,”
“believe,” “estimate,” “expect,” “forecast,” “intend,” “may,”
“plan,” “project,” “predict,” “should” and “will” and similar
expressions as they relate to the Company are intended to identify
such forward-looking statements. These forward-looking statements
are not guarantees of future performance; rather they are based on
the Management’s current expectations and assumptions about future
events and trends, the economy and other future conditions. The
forward-looking statements involve a number of known and unknown
risks and uncertainties. These risks and uncertainties and other
factors could materially adversely affect the outcome and financial
effects of the plans and events described herein. Actual results,
performance or events may differ materially from those expressed or
implied in such forward-looking statements and from expectations.
As a result, no undue reliance should be placed on such
forward-looking statements. This press release does not contain
risk factors. Certain risk factors that may affect the Company’s
future financial results are discussed in the published annual
financial statements of the Company. This press release, including
any forward-looking statements, speaks only as of the date of this
press release. The Company does not assume any obligation to update
any information or forward-looking statements contained herein,
save for any information required to be disclosed by law.
For more information, please contact:
Investor ContactStern IRJulie SeidelTel: +1
212-698-8684Email: SternIR-Vivoryon@sternir.com
Media ContactTrophic CommunicationsValeria
FisherTel: +49 175 8041816Email: vivoryon@trophic.eu
Vivoryon Therapeut (EU:VVY)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024
Vivoryon Therapeut (EU:VVY)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024